

## HR 6174

### Closing Loopholes for Orphan Drugs Act

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 27, 2016

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Sep 27, 2016)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/6174>

## Sponsor

**Name:** Rep. Welch, Peter [D-VT-At Large]

**Party:** Democratic • **State:** VT • **Chamber:** Senate

## Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Sep 27, 2016
Rep. Harper, Gregg [R-MS-3]	R · MS		Nov 17, 2016

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 27, 2016

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Sep 27, 2016)

### Closing Loopholes for Orphan Drugs Act

This bill amends the Public Health Service Act to revise the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program.

## Actions Timeline

- **Sep 27, 2016:** Introduced in House
- **Sep 27, 2016:** Referred to the House Committee on Energy and Commerce.